N/A
Completed N=74
Randomized Controlled Trial Comparing Two Different Morcellators for HoLEP Procedures
Benign Prostatic Hypertrophy Requiring Surgical Intervention
Source: ClinicalTrials.gov NCT02195622 ↗
Enrolled (actual)
74
Serious AEs
0.0%
Results posted
Mar 2019
Primary outcomePrimary: Morcellation Rate — 4.8; 5.6 grams/minute
Summary
To compare efficiency, in terms of tissue morcellation and removal time, of two commercially available FDA-approved morcellators: the VersaCut and the Piranha in subjects undergoing HoLEP procedure for benign prostatic hyperplasia (BPH).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Morcellation Rate |
4.8; 5.6 | — |
Eligibility Criteria
Inclusion Criteria
- Patients scheduled to undergo HoLEP for bladder outlet obstruction due to the prostate.
- Able to give informed consent.
- Age 18 years or older
Exclusion Criteria
- • Inability to give informed consent.
- Age less than 18 years
Data sourced from ClinicalTrials.gov (NCT02195622). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.